Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think the price it can achieve with a $18 to $20 million revenue is depends on what else we learn in the call. If we hear everything is going fine with generic Oxy and Vyvanse or some other unexpected event we should leap back up into the hot OTC territory. But regardless of what the short-term view you are focusing on is, this company is going to be sold in a couple of years for much more than shares are being sold at now. I am not going to hazard a guess other than to say I think it will be at least 5 times more than what it is now. To make crazy profits an investor has to be crazy patient.
Top 5 Reasons for a Vet Clinic to Offer IsoPet Treatments
(I consolidated several of their bullets to make a more easily consumed list)
https://isopet.com/the-isopet%C2%AE-blog/f/10-reasons-to-become-an-isopet%C2%AE-certified-veterinary-clinic
5. Contribute to advancement in veterinary medicine and best practices
4. Increase clinics reputation/visbility and staff technical capabilities
3. Improved professional network providing more opportunities/access to cutting edge technologies
2. Improve patient outcomes and better meet pet owners expectations
1. Increased revenue/client base
This upcoming quarter needs to be more than 10% higher than the last. I think this is possible based on the idea/hope that the Prasco sales in Dec were just a small part of the full sales made to Prasco for any given quarter. Meaning that I am optimistic that shipments to Prasco made from Jan to Mar could be double or triple whatever the Dec shipment was. I think it is safe to assume the Dec shipment wasn't very large given we saw only a 10% increase in revenue (not shabby but not enough to keep investors excited in an OTC stock). Without a 20% to 30% boost in revenue ($18 to $20 million) we will stay in the 11 to 13 cent range. Yes, I'm guessing another 5.5 months (3.5 months until 10Q w/o then another 1.5 months until next Q1) news that this could go down the 11s....
In Q3 CC I see that our working capital should start increasing at a faster clip. That would not be as impactful for short term increases but should provide more stability on the share price. The longer term OTC investor takes working capital seriously and it is certainly a tangible value that can't be argued with when a company is up for sale (which we know Elite will be in the relative near-term). The following is an explanation that Carter gave
All testing is done. The most critical testing (and followup analysis) of whether the product travels and is effective has been done for a very long time (i.e. the VX2 rabbit tests). The report of the test has been written and is being edited/reviewed now. The gentoxicity testing was completed Apr 1. Analysis of the results of gentoxicity testing is ongoing and should wrap up in the next couple of weeks. Then it has to be written up and reviewed. There is the hydrogel shelf-life study that this latest Apr summary declared done. If any of the testing has shown poor results they wouldn't be spending money to write up the analysis they would be figuring out what went wrong and how to address it. Thus all systems are ready for product launch!
With all physical testing done (I don't consider analysis of lab studies to be testing...rather it is analysis of the test results) and the company obviously making moves to move to a business model that treats human patients it is clear all testing was successful.
FYI, we already knew it would be because they had done VX2 testing before...FDA just wanted them to repeat it with more rabbits. The gentoxicity was a stupid thing to be asked to do because how Yi-90 affects tissue is very well known and radiogel hasn't done anything to that isotope to change that. No other company has been requested to do gentoxicity for a bracytherapy product. That was an FDA "I'm a big guy and can make you spend money and waste time" move.
So ALL testing is done.
Nice, this came out before the end of the trading day!!
I love their new tagline. It really fits the bill of how Radiogel/IsoPet works.
I recall they estimated the gentoxcity analysis was estimated to last 6 weeks in the Jan update. The date I saw them report the gentoxcity testing itself done was Apr 1 in the 2024 Q1 report. That would mean gentoxcity analysis should wrap up in mid-May.
They have not yet sent the rabbit testing (VX2) report to the independent review group. I would expect that would take at least 2 weeks to review with up to 2 weeks follow up (all that 6 weeks, 2 weeks to wrap up, 2 weeks for review, 2 weeks for back and forth). Putting that out to mid-Jun.
Hydrogel self-life is being finalized so that should get done in May.
So from my math it looks like mid-Jun is probably the most likely for IDE submisssion. With early or late June being when it actually occurs
The schedule has slipped because back in early Mar their estimates made it look like end of April. Not at all surprising and they should be taking extra care and not rushing. They may just consume most of Jun to allow themselves to be able to put the draft aside for a few days before re-re-reviewing it. When you spend so much time/energy on a document you need to distance your self from it on occasion to 'see' it clearly to get the best quality.
Yea, playing games like I suggested doesn’t help in the long term. And given I said “unless it’s bad news” that must have been on my mind. But independent of that angle an important reason to hold it to mon is to make it easy for new investors to understand the company. Who ever dumped at low prices today can’t have understood that the main catalysts are upcoming and reflect years of effort.
I guess we can hep by reposting the monthly link early next week. Investors need to understand what has been accomplished and how little work is ahead of us before IDE submission.
They should hold it until mon morning unless it’s bad news. No one is thinking of investments on a Fri night and X posts about it will be buried by mon.
Another intelligent, balanced article from Josh Enomoto
He takes a stab at a near-term price (he puts near-term upside target at around 38 cents to 50 cents). I think his estimate is reasonable estimate for $RDGL going into and after IDE submission.
Unfortunately he is ONLY looking at the market potential of global brachytherapy. Yes, radiogel can be a part of that, but unlike traditional brachytherapy it can also be used to treat most solid tumors. No one uses brachytherapy for sarcomas, yet sarcomas are pretty much what all uses of IsoPet have been directed toward. Unfortunately him not seeing that causes him to miss out on an extra at least $4 to $5 billion in potential market.
This was also written and posted this morning before the correction, but I think the correction was a needed and healthy move for us to have made.
https://www.barchart.com/story/news/25936943/barcharts-hot-penny-stocks-screener-identifies-opportunity-in-vivos-rdgl
They moved from a little shack out by an airport in no where land to downtown Kennewick (looks to be in/around a busy shopping district with a mall, stores, and chain restaurants surrounding them).
Price dipped below the 50 day moving avg (on 10 day time, 30 min time frame) and rebounded up....I think TA traders would be very happy with that. But I do not do TA and don't know which time frame matters for which moves. Any TA person that wants to talk about the dip and whether it was 'low' enough I would love to hear about that.
Some (maybe many) new investors just bought to ride the wave not understanding the company. As others pointed out we still have THE big catalyst in front of us of IDE submission and then the 30 day wait that is a price pusher in and of itself. There is supposed to be a Bezinga published in mid-Apr. I would like to see that soon, my best guess is they are waiting to for the final analysis of the genotoxicity to be done. Completion of that would be the end of the testing and everything would be in review or being written up.
The SEC filings link still broken on
https://vivosincusa.com/sec-filings
It is pointing to disabled site
https://www.radiogel.com/investors/sec-filings/
Probably will be moving it to the Vivos website as it seems related that the company not the radiogel product. Hope to see it up soon so new investors think they have their poop together.
Aren't we due a monthly report and benziga article...now would be a very good time for those.
IDE submission upcoming for a medical device that treats cancerous tumors via a liquid gel infused with Yi-90 injected into tumor and surrounding tissues. The gel hardens as soon as injected into the tumor. The Yi-90 treats the tumor locally. Radiation from Yi-90 doesn't travel far (millimeters) yet is highly energetic (kills cancer) and has a very short half life. After 10 days the tumor has died, the Yi-90 is no longer active (went through enough half lifes). Patient goes home day of the injections and immediately goes back to routine activities. Very few side effects other than swelling (think getting a mole frozen off).
Patient gets cancer in solid tumor killed in 1 treatment, with no surgery (meaning no scarring, no nerve damage, etc).
Website sets market potential as $7.5 billion in 2023 and up to $13 billion by 2030. It also alludes to all the companies that could be interested in partnering/buying company.
https://radiogelusa.com/prnt%E2%84%A2
The website doesn't need to list dozens of cancer types RadioGel can help because it states that more elegantly by simply stating "Y-90 RadioGel™ is a device designed for radiation treatment of solid tumors."
So it can be applied to any cancer type/location that involves a solid tumor.
That is a very long list that omits things like leukemia and such.
I think it is gone, thank you!
Response to BDD was wild, response to upcoming IDE submission was muted and almost non-existent for more than a month. Price of 0.05 to 0.06 in Feb when we KNEW that IDE would be submitted in a few months was super crazy. Since then price has been climbing at a relatively stable rate without giant jumps. Even now with a market cap $70 million it is underpriced.
This a product that is not only a Brachytherapy device, but can also be used in place of surgery to treat almost any solid tumor. Not only treat them but treat them more effectively and with fewer side effects. That is a billion dollar market!!
Top that off with that it has been used in animals for years without a single negative impact or unexpected result.
They will submit IDE to FDA sometime before end of Jun (stock jumps) then a 30 day clock starts. If FDA doesn't have a problem with the IDE they will say nothing, the clock expires meaning IDE is approved by not being rejected (stock jumps). Then Mayo doctors submits request to do clinical trials (stock may jump) and Mayo clinic approves trials (stock jumps).
Then trials start and radiogel proves itself in humans and word spreads.
I am hesitant to try to guess future prices of penny stocks. The OTC is just too crazy. It could be way lower than any of us expect (this is probably off the table given the price action going on right now....the train is leaving the station and it is starting out in a pretty high gear) to much higher than any of us dreamed. Market cap should give us a hint. With a value of about $60M we have alot of room to increase. I think a market cap of a few hundred million is reasonable. So I think we should see at a minimum 4 to 5 times increase from here. We probably should have already had a $100M market cap. In my opinion this stock has been greatly undervalued. When a stock captures investors attention wild things can happen so the highest it goes could be higher than it really should get.
Above related to price before IDE submission. I think price after is largely a function of price before so I'm not even thinking about that.
That information is in the table at the bottom of the board....I"m thinking your just asking to get it posted and know it yourself? If not, wow, pay attention to the details of the OTC you invest in! The first two (filed earliest) are the ones that have passed their PDUFA date. I do not think they will necessarily be approved before the end of June. I think the FDA came back with questions and Nasrat had to look at everything going on and decide if pulling someone away from their day job or spending any more money to satisfy questions from FDA on po-dunk products was worth it. Other items Elite has going on that maybe more important includes:
- answering any questions related to Oxy and Vyvanse
- setting up new packaging facilities
- keep research/progress moving on new $billion dollar market products
Dopamine Agonist 12 M Filed with FDA - 22 Dec 2022 ---------- ----------
Antimetabolite 42 M Filed with FDA - 20 Apr 2023 ---------- ----------
Generic OxyContin 720 M Filed with FDA - 17 Aug 2023 ---------- ----------
Generic Vyvanse 5.1 B Filed with FDA - 21 Dec 2023 14 ----------
Want to add a "thank you!" the people/peoples that keep the table of products up to date. It is a very helpful resource that gives new and existing investors a quick overview of current and future potential.
Thanks Sharkey1! Looks like you have been out several years or are you still holding some RDGL? Both my OTC investments (this and Elite) have finally been pulling things together this year. I have believed and been in both many years, and at this point I have same number of shares (multiple 7 digits) at about the same each price average (about 0.07 cents). I strongly believe in both companies success. I think Elite's rise will continue but will be slow and relatively consistent until the company is sold (hopefully going out with a bang!). RDGL, if it gets the IDE will probably hit a price point that Elite can't touch for sometime if ever, but if it gets denied it will be in the toilet again, probably forever. The issue is that IDE acceptance should be a slam dunk because RDGL has been the FDAs little bitch for years now doing whatever it wants, however it wants it. But FDA really can't be trusted to do the 'right' thing because many of the people working there have future jobs lined up with companies that act as their puppet masters. It sure is nice to have my stress be related to 'how much do profit do I take and when' for a change!
I think they are delaying article to maximize what it reports. They should complete both geneotxicity and rabbit study in their entirety in the next week or two at most. The article coming out after that would be nice.
It didn’t go up because of a stupid tweet or post. It went up because time is running out between now and the IDE being submitted. Today is proof that tweets and posts don’t matter because none of those had anything in them that was new.
Flippers are getting in now that we are close to IDE submission because they done have patience to buy low and hold. Anyone reading this board that had spare cash that did not load up in Feb when we hit .05 (knowing all the big lifts required for IDE were wrapping up) was dumb as dirt. I increased my holdings then by several hundred thousand shares.
That post is OK because it clarifies why they think they are a leader. Having the most patents though is not a measure that most use to identify a leader. I also doubt they have the most patents of any company related related to bracytherapy. Before you get your panties in a bunch I believe in the company and have been invested (in and out) for about as long as anyone here. I also know most of those patents are expired and that the patents they hold just for themselves is more like a half dozen and many of those are related to one another. I keep close track of those patents. The patents are 'good' in the sense I think they protect the company from competitors even in light of the expired Battelle patents (because the push the technology out in a way a company needs to be profitable and meet needed safety regulations).
I also agree they are on the forefront of changing the way brachytherapy is done and the way some cancerous tumors are treated. Radiogel is going to be a new technology that changes how doctor's treat certain cancers and give patients a superior outcome and quality of life during and after treatment (external beam and invasive surgeries cause damage that doesn't resolve).
We are still due an update on the genotoxcity testing. It was supposed to wrap up the analysis by mid-April. Perhaps they will also send that out to Pearl Pathways.
Anywhoo, I have been having 5 digit increases in my account daily...with IDE that will be a juicy 6 figure amount. So I am a very happy investor. I'll read the filler BS posts on X on days they don't have anything new to say and keep my thoughts about them to myself.
Huh? The statement they made is
"We are the leaders in radionuclide therapy!"
So radionuclide therapy is the qualifier. In case you don't know the definition of radionuclide therapy is defined as a type of cancer treatment that uses radioactive substances (radionuclides) to kill cancer cells or to prevent them from growing and dividing. This therapy involves administering radioactive substances either orally or intravenously, which then travel through the bloodstream and accumulate in cancerous cells or tissues.
So they are claiming they are leaders in treating cancer with the use of radioactive substances.
It will AFTER radiogel proves itself. There are no tangible metrics for them to state that as fact. They can say they believe they are leaders, but an absolute statement is ridiculous at this stage.
ChatGPTs interpretation notes the needs for measureable metrics. Vivos/radiogel doesn't meet any of the noted metrics for 'leader'.
Your wrong. The clock to the end of this quarter is winding down. The company has announced that they will submit an IDE this quarter. Investors are starting to puchase shares in anticipation of that submission. Its a golden, short-term FDA play. THAT is why the stock has started to move. Many of us announced this expected increase to begin and last as the weeks of this quarter play out as the quarter progresses.
Some investors (why do you assume longs? The posts on X just started in the past 6 months, I do not call those longs) have been doing what they are for months. It has nothing to do with price action now.
To claim all increases since 0.06 is because of attempts by retail to promote stock is STOOOPID and ignores the entire fact that the company made some significant announcements since 0.06. Its STOOPID because if what you say were true (that this stock is moving because of investors promoting it and nothing esle) this would be a pump and dump investment. Which is is NOT.
Schwab does not agree that .1203 was hit after close.
I'm not a fan of the new marketing hires that apparently have 'post something everyday' in their contract. A good percentage of the posts on X add have no meaningful value in terms of information. Todays is incredibly repetitive and includes a blatant falsehood "We are the leaders in radionuclide therapy!".
How can they be the leaders in radionuclide therapy when it has never been used in a human patient.
It also describes Yi-90 without even stating that it is the radionuclide that Vivos product uses. No thought put into these slides just push shit out to meet some metric.
We are the leaders in radionuclide therapy! $RDGL pic.twitter.com/y1k2Tgw4qa
— Vivos Inc. (@VivosIncUSA) April 24, 2024
Their latest post to X makes it sound like there has been have multiple IsoPet treatments this week. I wonder if they finally pulled off a multiple treatment with one batch of gel move. They talked about that in the past but I don't think it ever came to fruition. That would be amazing if they did as it would lower the overall cost to the patients and probably increase profit (they would share alot, but not all cost savings...cause that is what for profit companies do...). The path to IsoPet becoming profitable is having enough clinics to consistently bring in revenue. If they keep adding 3 to 4 a quarter maybe they can pull that off in the relative near term.
More cats, dogs and horses are being treated in our regional clinics across the USA this week! We will update when we can and thank you to our followers for helping get the word out! Animals now, humans next! $RDGL #IsoPet #RadioGel #VivosIncUSA #Cancer pic.twitter.com/vlBUu0UGwH
— IsoPet® Cancer Treatment (@IsoPetForCancer) April 23, 2024
Agree that Prasco should be bigger. It still can as the Dec sales was a single, kick off shipment. We don't know if it is the typical size of a typical quarters manufacturing level for Prasco. Drop is also because approval of 2 drugs with combined market value of about $50 million did not occur on expected timeline. That may have bothered some investors in that it illustrates that drug approvals can't be taken for granted and that a submission doesn't really have value unless/until its approved.
PE is getting really low, with two months left an amazing buy opportunity could come up if some with large holdings decide to liquidate. Definitely keeping my eye out to take advantage of such impatience.
Good grief! They want a 5 year lease because they see themselves needing the extra space for the long-term. The reason the question was stupid because 'bubba' asked why would Elite sign a 5 year lease agreement if they can see selling the company in 2 years. If the lease was only for 2 years it would make the company less attractive to a prospective buyer because the new owner would have to figure out how to solve the space problem again and that space is a sweet solution for Elite (sweet = economic and convenient) . In most (maybe all...?) states the new owner has to honor the previous owners lease agreements made with the original owner or management, unless the lease agreement specifically states that the lease will terminate in such case. In Elite's case this is a benefit. The new owner will need the space just like Elite. So Elite having the space wrapped up for 5 years will facilitate a sale.
Agreed.
I doubt it will be 'like' the opioid crisis. Are people ODing, losing their jobs?, using all their money to buy the drug?, stealing?, does it lead to heroin use, once they start a dose does that amount stop working and they have to take more and more to get the same effect?
I wouldn't even compare it to alcohol. Someone on alcohol is a PITA and if driving, dangerous to others. Someone on adderall maybe more productive and focused....horrifying!!
Kind of stupid to compare the two if you ask me.
Thank you! Interesting in that the clinic had gone through training which means that they actually used the product. This doesn't worry me as there could be any number of reasons and I did find it odd/interesting that a surgical center was wanting to use the product. I thought this because IsoPet is a product that could decrease the number of surgeries they do. If you look at the website for the NY Surgical Center on Long Island almost all services offered are related to surgery and rehabilitation from surgery. Yes, treating margins is a valid use of radiogel/isopet. But if you were a pet owner might you not want to ask..."why not skip the surgery and just do the injection of IsoPet then we can see if we need surgery at all"?. My belief is you shouldn't go to a surgeon unless/until you have decided you need surgery because surgeons love to cut! The prospect of using Radiogel and cutting less probably didn't sound appealing to some if not most of their surgeons. Plus it probably would have been less profitable. My guess is one or two forward looking surgeons there wanted it but the clinic as a whole decided it didn't fit.
I didn't forget! I had been wanting to hear the results of that use case, so based on your comment I went through this years 10K just now to see if that clinic was still mentioned and it was not. In the March 2023 10K a clinic was mentioned that had gotten training and part of their plan was to specifically test the use of radiogel around skin that had surrounded a tumor surgically removed. This years 10K doesn't mention that center so for some reason it never finished the necessary requirements and started using radiogel. Sure would like to know why....wonder if it was an issue with getting their Radioactive Material Handling License. That might have been too costly in NY or at least difficult.
From last years (not this March but March 2023 10K)....
Yes, it will be new revenue source reported next quarter. I'm still also expecting a pretty good bump up in Adderall sales from Prasco adderall sales. A million and a half increase in revenue from Prasco doesn't seem like anywhere near a full quarters worth of Prasco adderall sales. I think it may have been a small batch just to get things kicked off. Lots of time for anyone with a brain and spare cash to get in. Price could even go down from here. If it does, do NOT sell. I don't think I have ever posted such an explicit statement like that. But it is frustrating to see people cave at the exact wrong time. I'm in an FDA play where that company is running late on submitting an investigational device application. Its starting to build in price as that submission was announced by the company to be this quarter....and people sold at a 25% increase......before the application was submitted. There is no way it will not be submitted. It maybe denied but it will be submitted and it will increase at least 4 fold when that happens. Poor shumcks have since posted their regret because price is now 100% up.
Anyway. This is THE WRONG time to sell. If it goes lower, still don't sell. Maybe buy but do not sell. Elite has soo many irons in the fire for greatly increased revenue it would be super dumb to bail now!!
Another potential catalyst in the near-term is government regulation to make manufacturing generic drugs more profitable. I think the government could pass such legislation before the November election because it would give Biden an opportunity to point to something it has accomplished.
One of the fundamental reasons there are drug shortages is because the generic drug market forces manufacturers to sell the drugs at a price that barely covers their costs. Meaning little to no profit so little to no incentives to produce generic drugs. The government has been repeatedly acknowledging that price incentive is a root cause of these drug shortages and that something needs to be done to encourage manufacturers to invest in producing generic drugs. The latest press release I found about this is from April 2 (https://www.hhs.gov/about/news/2024/04/02/hhs-releases-white-paper-focused-preventing-drug-shortages.html).
ELTP price has quadruple in the past year. How many stocks do that? Its taking a breather before its next move that will come this summer.
It sat at $0.03 cents for several months after we were told of upcoming ANDA submissions with market values in the billions. That was inexplicable but it happened and those who ignored others inaction have reaped the benefits of those gains. The price increase since then has stabilized giving anyone who invested at 0.03 ample opportunity to get at a minimum a 400% return. Anyone who bought in the months we traded in the 0.03 to 0.04 range and wanted to lock in profit probably got sold shares with 600% gains.
Here we are again at a price point that makes no sense. Will you be someone how hesitates because the masses don't see a good thing? Or are you someone who sees the opportunity and trusts their own DD over markets inaction. FYI, namtae these are rhetorical questions for anyone who reads this other than you. I'm not interested in your reply.
I was wrong. I didn't expect the dip this morning, definitely a better time to buy now than yesterday afternoon.
....Update, less than 15 minutes later the opportunity may have passed....